A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Once-Weekly DPP-4 Inhibitors of MSD, Takeda to Bring New Dimension to Packed Market
October 15, 2013
-
BUSINESS Gilead to Enter Japan Full Force with Hepatitis C Treatment
October 11, 2013
-
REGULATORY CSIMC Pricing Subcommittee to Explore “Responses” to Diovan Uproar
October 10, 2013
-
ORGANIZATION Japan Self-Medication Industry Requests Health Minister to Remove JMA, JPA Members from OTC Drug Review Council
October 9, 2013
-
ORGANIZATION Blanket 14-Day Prescription Limit Should Be Scrapped: EFPIA Japan Chair
October 8, 2013
-
BUSINESS Quintiles Aims to Expand Business in Japan with More Employees: CEO
October 8, 2013
-
BUSINESS 3 Combination Drugs for Asthma, COPD Get Approval to Fuel Competition; NHI Price Listing Expected in November
October 7, 2013
-
ORGANIZATION Diovan Issue is “Isolated Example,” Confidence in Japan Clinical Trials Not Lost: President Viehbacher of EFPIA
October 7, 2013
-
REGULATORY NIBIO to Strengthen Academia’s Drug Discovery Support Initiatives in Order to Evaluate 400 Research Themes by FY2015
October 4, 2013
-
ORGANIZATION JPMA Compliance Committee to Decide Penalties for Novartis for Diovan Case as Requested by Dr Teshirogi
October 3, 2013
-
BUSINESS Another Administrative Action Taken Against MTPC on Medway Injection; 3rd in 4 Years
October 2, 2013
-
REGULATORY Interim Report of Diovan Panel Fails to Lay Bare Who Altered Data, for What Purpose
October 1, 2013
-
BUSINESS Amgen Astellas BioPharma to Go on Stream Oct. 1; JV Chief Takahashi Eager to Make It a “Category Leader”
September 30, 2013
-
REGULATORY Japan Health Minister Meets Exec of Swiss Novartis, Seeks Cooperation in Diovan Probe
September 27, 2013
-
REGULATORY JPWA Seeks Generic Name Listing for Wider Range of Generics
September 27, 2013
-
BUSINESS 3 Pharma Groups Demand Permanent Introduction of Premium at CSIMC; Healthcare Rep Still Wary
September 26, 2013
-
BUSINESS Daiichi Sankyo Dogged by Renewed Quality Woes at Ranbaxy; FDA Mute on Details
September 26, 2013
-
ACADEMIA National University Hospital Council Urges Immediate Check-Up on Hospital’s Clinical Research Systems
September 25, 2013
-
BUSINESS Unique Marketing System Jacks Up Profits at Vital KSK; Customer-by-Customer Cost Analyses Lend Support
September 24, 2013
-
REGULATORY FTC’s Legal Intervention in Diovan Issue Possible, but Only with New Facts: Lawyer
September 20, 2013
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…